**Antimicrobials Evaluation Committee Meeting**

**Minutes:** Unconfirmed

**Date and Time:** Monday 24 January 2022 at 9am

|  |  |  |
| --- | --- | --- |
| **Present:** | 1. Amanda Adler (Chair)
 | Present for all notes |
|  | 1. Colin Brown
 | Present for all notes |
|  | 1. Mike Chambers
 | Present for all notes |
|  | 1. Mark Chapman
 | Present for all notes |
|  | 1. Tim Felton
 | Present for all notes |
|  | 1. Neil Ferguson
 | Present for all notes |
|  | 1. Neil Hawkins
 | Present for all notes |
|  | 1. Andrew Hitchings (Vice chair)
 | Present for all notes |
|  | 1. Alison Holmes
 | Present for all notes |
|  | 1. Philip Howard
 | Present for all notes |
|  | 1. Peter Jackson
 | Present for all notes |
|  | 1. Alistair Leanord
 | Present for all notes |
|  | 1. Malcolm Oswald
 | Present for all notes |
|  | 1. David Partridge
 | Present for all notes |
|  | 1. Matt Stevenson
 | Present for all notes |
|  | 1. Nicky J Welton
 | Present for all notes |
| **In attendance:** |  |  |
| Nick Crabb | Programme Director, National Institute for Health and Care Excellence | Present for all notes |
| Sophie Cooper | Scientific Adviser, National Institute for Health and Care Excellence | Present for all notes |
| Charlotte Downing | Project Manager, National Institute for Health and Care Excellence | Present for all notes |
| Pratit Shah | Administrator, National Institute for Health and Care Excellence | Present for all notes |
| Caroline Bregman | Technical Analyst, National Institute for Health and Care Excellence | Present for all notes |
| James Love-Koh | Technical Analyst, National Institute for Health and Care Excellence | Present for all notes |
| Jacoline Bouvy | Technical Director, National Institute for Health and Care Excellence | Present for all notes |
| Colm Leanord | Consultant Clinical Advisor, National Institute for Health and Care Excellence | Present for all notes |
| Mandy Tonkinson | NICE PIP representative, National Institute for Health and Care Excellence | Present for notes 1 to 4 |
|  |  |  |
|  |  |  |
| **Non-public attendees:** |  |  |
| Nicola Andrews | Anthony Nolan patient nomination,Patient expert | Present for notes 1 to 4 |
|  |  |  |
| Tom Ashfield | Senior Medical Affairs Advisor, PfizerCompany representative  | Present for notes 1 to 4 |
|  |  |  |
| Arlene Brailey | Patient Support Team Lead, Antibiotic Research UK,Patient expert | Present for notes 1 to 4 |
|  |  |  |
| Nick Brown | Consultant Medical Microbiologist, Cambridge University Hospitals NHS Foundation Trust,Clinical expert | Present for notes 1 to 4 |
|  |  |  |
| David Glover | Assistant Director of Medicines Analysis, Medicines Policy Unit, NHS England and NHS Improvement,NHS commissioning expert | Present for notes 1 to 4 |
|  |  |  |
| Sue Harnan | Project team, Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) | Present for notes 1 to 4 |
|  |  |  |
| Patrick Holmes | Science and Innovation Policy Lead, Pfizer,Company representative  | Present for notes 1 to 4 |
|  |  |  |
| Dina Jankovic | Project team, Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) | Present for notes 1 to 4 |
|  |  |  |
| Ben Kearns | Project team, Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) | Present for notes 1 to 4 |
|  |  |  |
| Jack Kowalik | HTA Manager, Pfizer,Company representative | Present for notes 1 to 4 |
|  |  |  |
| Marisa Lanzman | Senior Pharmacist, Royal Free London NHS Foundation Trust,Clinical Expert | Present for notes 1 to 4 |
|  |  |  |
| Mark Sculpher | Project team, Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU)  | Present for notes 1 to 4 |
|  |  |  |
| Andrew Seaton | Consultant in Infections Diseases and General Medicine, NHS Greater Glasgow and Clyde,Clinical expert | Present for notes 1 to 4 |
|  |  |  |
|  |  |  |

**Notes**

**Any other Business**

1. None

**Appraisal of ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections**

**Part 1 – Open session**

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (EEPRU) representatives and representatives from Pfizer.
2. (Link to committee AMR register of interests)

The Chair asked all committee members, experts, EEPRU representatives and NICE staff present to declare any relevant interests that had not already been recorded on the register.

* 1. Alison Holmes declared an indirect interest as co-supervisor of a PhD fellowship funded through a collaborative programme involving industry partnerships including Shionogi.
		1. It was agreed that this declaration would not prevent Alison Holmes from participating in this section of the meeting.
	2. Tim Felton declared a direct non-financial interest as the chief investigator at the phase three UK clinical trial for the Menarini group compound meropenem vaborbactam. He had shared his experience with the company at a UK advisory board in 2019.
		1. It was agreed that this declaration would not prevent Tim Felton from participating in this section of the meeting.
	3. Tim Felton declared a direct non-financial interest as he holds a number of leadership roles within Manchester University NHS Foundation Trust relating to antimicrobial stewardship.
		1. It was agreed that this declaration would not prevent Tim Felton from participating in this section of the meeting.
	4. No further conflicts of interest were declared for this appraisal.
1. Presentation by the Chair and Lead Team: Phil Howard and Neil Hawkins.
2. The committee considered the evidence submitted by Pfizer (the company that manufactures ceftazidime–avibactam) and other stakeholders, the assessment report from the Policy Research Unit in Economic Methods of Evaluation in Health and Social Care Interventions (EEPRU), and consultation comments on EEPRU’s report from stakeholders. See the committee papers for full details of the evidence. The committee agreed its preferred approach to estimating the benefits of ceftazidime–avibactam based on the options presented by EEPRU. The committee also considered whether EEPRU’s economic analysis had underestimated the benefits of ceftazidime–avibactam, and estimated the size of the population eligible for ceftazidime–avibactam.

**Part 2 – Closed session (company representatives, clinical and patient experts, EEPRU representatives and members of the public were asked to leave the meeting)**

1. The committee agreed the content of the draft guidance, including:
* the population eligible for ceftazidime–avibactam, including recommendations on good antimicrobial stewardship
* the most plausible estimate of the incremental population net health benefits of ceftazidime–avibactam to the NHS over the modelled time horizon, measured in quality-adjusted life years (QALYs)
* what proportion of the total incremental population net health benefits NHS England should assign to the contract period, in QALYs
* recommendations for research and data collection.
1. The committee’s conclusions and recommendations were based on majority opinion.
2. The committee asked the NICE technical team to prepare the draft guidance document in line with their decisions.